Do we need randomized clinical trials in extracorporeal respiratory support? Yes

Alain Combes, Antonio Pesenti, Daniel Brodie

Research output: Contribution to journalArticle

Abstract

Extracorporeal respiratory support, also known as extracorporeal gas exchange, may be used to rescue the most severe forms of acute hypoxemic respiratory failure with high blood flow venovenous extracorporeal membrane oxygenation. Alternatively, lower flow extracorporeal carbon dioxide removal might be applied to reduce the intensity of mechanical ventilation in patients with less severe forms of the disease. However, critical reading of the results of the randomized trials and case series published to date reveals major methodological biases. Older trials are not relevant anymore since the ECMO circuitry was not heparin-coated leading to severe hemorrhagic complications due to high levels of anticoagulation, and because extracorporeal membrane oxygenation (ECMO) and control group patients did not receive lung-protective ventilation. Alternatively, in the more recent CESAR trial, many patients randomized to the ECMO arm did not receive ECMO and no standardized protocol for lung-protective mechanical ventilation existed in the control group. Since these techniques are costly and associated with potentially serious adverse events, there is an urgent need for high-quality data, for which the cornerstone remains randomized controlled trials.

Original languageEnglish
Pages (from-to)1862-1865
Number of pages4
JournalIntensive Care Medicine
Volume43
Issue number12
DOIs
Publication statusPublished - 2017

Fingerprint

Extracorporeal Membrane Oxygenation
Randomized Controlled Trials
Artificial Respiration
Lung
Control Groups
Carbon Dioxide
Respiratory Insufficiency
Ventilation
Heparin
Reading
Gases

Keywords

  • Acute respiratory distress syndrome
  • Editorial
  • Extracorporeal CO removal
  • Extracorporeal membrane oxygenation
  • Mechanical ventilation

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Do we need randomized clinical trials in extracorporeal respiratory support? Yes. / Combes, Alain; Pesenti, Antonio; Brodie, Daniel.

In: Intensive Care Medicine, Vol. 43, No. 12, 2017, p. 1862-1865.

Research output: Contribution to journalArticle

@article{76128ad03ba1402ebdbed0fdc7d5ea4c,
title = "Do we need randomized clinical trials in extracorporeal respiratory support? Yes",
abstract = "Extracorporeal respiratory support, also known as extracorporeal gas exchange, may be used to rescue the most severe forms of acute hypoxemic respiratory failure with high blood flow venovenous extracorporeal membrane oxygenation. Alternatively, lower flow extracorporeal carbon dioxide removal might be applied to reduce the intensity of mechanical ventilation in patients with less severe forms of the disease. However, critical reading of the results of the randomized trials and case series published to date reveals major methodological biases. Older trials are not relevant anymore since the ECMO circuitry was not heparin-coated leading to severe hemorrhagic complications due to high levels of anticoagulation, and because extracorporeal membrane oxygenation (ECMO) and control group patients did not receive lung-protective ventilation. Alternatively, in the more recent CESAR trial, many patients randomized to the ECMO arm did not receive ECMO and no standardized protocol for lung-protective mechanical ventilation existed in the control group. Since these techniques are costly and associated with potentially serious adverse events, there is an urgent need for high-quality data, for which the cornerstone remains randomized controlled trials.",
keywords = "Acute respiratory distress syndrome, Editorial, Extracorporeal CO removal, Extracorporeal membrane oxygenation, Mechanical ventilation",
author = "Alain Combes and Antonio Pesenti and Daniel Brodie",
year = "2017",
doi = "10.1007/s00134-017-4933-7",
language = "English",
volume = "43",
pages = "1862--1865",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Do we need randomized clinical trials in extracorporeal respiratory support? Yes

AU - Combes, Alain

AU - Pesenti, Antonio

AU - Brodie, Daniel

PY - 2017

Y1 - 2017

N2 - Extracorporeal respiratory support, also known as extracorporeal gas exchange, may be used to rescue the most severe forms of acute hypoxemic respiratory failure with high blood flow venovenous extracorporeal membrane oxygenation. Alternatively, lower flow extracorporeal carbon dioxide removal might be applied to reduce the intensity of mechanical ventilation in patients with less severe forms of the disease. However, critical reading of the results of the randomized trials and case series published to date reveals major methodological biases. Older trials are not relevant anymore since the ECMO circuitry was not heparin-coated leading to severe hemorrhagic complications due to high levels of anticoagulation, and because extracorporeal membrane oxygenation (ECMO) and control group patients did not receive lung-protective ventilation. Alternatively, in the more recent CESAR trial, many patients randomized to the ECMO arm did not receive ECMO and no standardized protocol for lung-protective mechanical ventilation existed in the control group. Since these techniques are costly and associated with potentially serious adverse events, there is an urgent need for high-quality data, for which the cornerstone remains randomized controlled trials.

AB - Extracorporeal respiratory support, also known as extracorporeal gas exchange, may be used to rescue the most severe forms of acute hypoxemic respiratory failure with high blood flow venovenous extracorporeal membrane oxygenation. Alternatively, lower flow extracorporeal carbon dioxide removal might be applied to reduce the intensity of mechanical ventilation in patients with less severe forms of the disease. However, critical reading of the results of the randomized trials and case series published to date reveals major methodological biases. Older trials are not relevant anymore since the ECMO circuitry was not heparin-coated leading to severe hemorrhagic complications due to high levels of anticoagulation, and because extracorporeal membrane oxygenation (ECMO) and control group patients did not receive lung-protective ventilation. Alternatively, in the more recent CESAR trial, many patients randomized to the ECMO arm did not receive ECMO and no standardized protocol for lung-protective mechanical ventilation existed in the control group. Since these techniques are costly and associated with potentially serious adverse events, there is an urgent need for high-quality data, for which the cornerstone remains randomized controlled trials.

KW - Acute respiratory distress syndrome

KW - Editorial

KW - Extracorporeal CO removal

KW - Extracorporeal membrane oxygenation

KW - Mechanical ventilation

UR - http://www.scopus.com/inward/record.url?scp=85029525040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029525040&partnerID=8YFLogxK

U2 - 10.1007/s00134-017-4933-7

DO - 10.1007/s00134-017-4933-7

M3 - Article

AN - SCOPUS:85029525040

VL - 43

SP - 1862

EP - 1865

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

IS - 12

ER -